Lobaplatin

DB13049InvestigationalSmall molecule

Lobaplatin has been used in trials studying the treatment of Breast Cancer, Hepatocellular Carcinoma, and Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma.

Mechanism: Pharmacologically active on DNA
Curator reviewed
Formula / weight: C₉H₁₈N₂O₃Pt · 397.338 g/mol (avg)

Resolves to

Compound

UNIIOX5XK1JD8CCAS135558-11-1

Structure

InChIKeyRLXPIABKJFUYFG-DOYDWZMXSA-MSMILES[Pt++].C[C@H]([O-])C([O-])=O.NC[C@@H]1CC[C@H]1CN

What you can answer from here — as of August 27, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

27Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Lobaplatin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account